A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

study id #: NCT03779334

condition: Muscular Atrophy, Spinal

status: Recruiting

purpose:

A global study of oral risdiplam in pre-symptomatic participants with spinal muscular atrophy (SMA).

intervention: Risdiplam

results: https://clinicaltrials.gov/ct2/show/results/NCT03779334

last updated: February 04, 2022

start date: August 7, 2019

estimated completion: January 21, 2029

last updated: December 21, 2021

phase of development: Phase 2

size / enrollment: 25

study description: The study is an open-label, single-arm, multicenter clinical study to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of risdiplam in infants aged from birth to 6 weeks who have been genetically diagnosed with SMA but are not yet presenting with symptoms. There will be a screening, treatment, open-label extension (OLE) and a follow-up. All participants will receive risdiplam orally once daily for 2 years followed by an OLE phase of at least 3 years and a follow-up, for a total treatment duration of at least 5 years for each participant enrolled.

primary outcomes:

• Percentage of participants with two copies of the survival motor neuron (SMN) 2 gene (excluding the known SMN2 gene modifier mutation c.859G>C) and baseline compound muscle action potential (CMAP) >=1.5 millivolt (mV) who are sitting without support
  Sitting is defined as "sits without support for 5 seconds" as assessed in Item 22 of the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) Gross Motor Scale
• At Month 12
  

secondary outcomes:

• Percentage of participants developing clinically manifested SMA
  At Month 12 and 24
• Time to permanent ventilation and/or death
  Up to 7 years
• Percentage of participants who are alive without permanent ventilation
  At Month 12 and 24
• Percentage of participants alive
  At Month 12 and 24
• Percentage of participants who achieve the attainment level of the motor milestones as assessed in the Hammersmith Infant Neurological Examination-2 (HINE-2)
  At Month 12 and 24
• Percentage of participants with two copies of the SMN2 gene sitting without support for 5 seconds (independent of the CMAP value at baseline).
  At Month 12
• Percentage of participants sitting without support for 5 seconds
  At Month 24
• Percentage of participants sitting without support for 30 seconds
  At Month 12 and 24
• Percentage of participants standing for at least 3 seconds
  At Month 24
• Percentage of participants walking (takes at least 3 steps)
  At Month 24
• Percentage of participants demonstrating the ability to achieve a scaled score on BSID-III Gross Motor Subtests within 1.5 standard deviations of chronological reference standard
  At Month 24 and 42
• Change from baseline score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale
  At Month 12
• Percentage of participants who achieve a score of 40 or higher, 50 or higher, and 60 or higher in the CHOP INTEND motor function scale
  At Month 12
• Percentage of participants who meet CHOP INTEND stopping criteria at any point
  Up to Month 24
• Change from baseline in the Hammersmith Functional Motor Scale Expanded (HFMSE) score
  At Month 60
• Number and percentage of participants within 3rd percentile of normal range for weight-for-age, length/height-for-age and weight-for-length/height
  At Month 12, 24, 36, 48 and 60
• Number and percentage of participants within 3rd percentile of normal range for head circumference-for-age
  At Month 12 and 24
• Change from baseline percentiles for weight-for-age, length/height-for-age, and weight-for- length/height
  At Month 12, 24, 36, 48 and 60
• Change from baseline percentiles for head circumference- for-age
  At Month 12 and 24
• Change from baseline in chest circumference
  At Month 12 and 24
• Ratio between chest and head circumferences
  At Month 12 and 24
• Percentage of participants with the ability to swallow and to feed orally
  At Month 12, 24, 36, 48 and 60
• Change from baseline in compound muscle action potential (CMAP) amplitude
  At Month 12 and 24
• Measurement of pharmacodynamic marker levels in blood
  Day 1, 56, 196, 364, 728 and at early withdrawal
• Percentage of participants with adverse events
  Up to 7 years
• Ophthalmological examination as appropriate for age
  Up to 7 years
• Plasma concentration of risdiplam and its metabolites to characterize the PK profile
  Up to 7 years

inclusion criteria:

Inclusion Criteria:

Males and females aged from birth (1 day) to 6 weeks (42 days) of age at the time of first dose (Day 1); a minimum age of 7 days at first dose is required for the first infant to be enrolled
Gestational age of 37-42 weeks for singleton births; gestational age of 34-42 weeks for twins
Body weight >= 3rd percentile for age, using appropriate country-specific guidelines
Genetic diagnosis of 5q-autosomal recessive SMA, including confirmation of homozygous deletion or compound heterozygosity predictive of loss of function of the SMN1 gene
Absence of clinical signs or symptoms at screening (Day -42 to Day -2) or at baseline (Day -1) that are, in the opinion of the investigator, strongly suggestive of SMA
Receiving adequate nutrition and hydration at the time of screening, in the opinion of the investigator
Adequately recovered from any acute illness at baseline and considered well enough to participate in the study, in the opinion of the investigator
Able and expected to be able to safely travel to the study site for the entire duration of the study and in accordance to the frequency of required study visits, in the opinion of the investigator
Able to complete all study procedures, measurements, and visits, and the parent (or caregiver), in the opinion of the investigator, has adequately supportive psychosocial circumstances
Parent (or caregiver) is willing to consider nasogastric, naso-jejunal, or gastrostomy tube placement during the study to maintain safe hydration, nutrition, and treatment delivery, if recommended by the investigator
Parent (or caregiver) is willing to consider the use of non-invasive ventilation during the study, if recommended by the investigator

exclusion criteria: Criteria:

Concomitant or previous participation in any investigational drug or device study at any time
Concomitant or previous administration of an SMN2-targeting antisense oligonucleotide, SMN2-splicing modifier, or gene therapy either in a clinical study or as part of medical care
Presence of significant concurrent syndromes or diseases
In the opinion of the investigator, inadequate venous or capillary blood access for the study procedures
Requiring invasive ventilation, tracheostomy or awake non-invasive ventilation
Awake hypoxemia (SaO2 < 95%) with or without ventilator support
Multiple or fixed contractures and/or hip subluxation or dislocation at birth
Systolic blood pressure or diastolic blood pressure or heart rate considered to be clinically significant by the investigator
Presence of clinically relevant ECG abnormalities before study drug administration; corrected QT interval using Bazett's method > 460 ms; personal or family history (first degree relatives) of congenital long QT syndrome indicating a safety risk for patients as determined by the investigator. First-degree atrioventricular block or isolated right bundle branch block are allowed
The infant (and the mother, if breastfeeding the infant) taking any inhibitor of CYP3A4 taken within 2 weeks, any inducer of CYP3A4 taken within 4 weeks, any OCT 2 and MATE substrates within 2 weeks and known FMO1 or FMO3 inhibitors or substrates
Clinically significant abnormalities in laboratory test results
Ascertained or presumptive hypersensitivity to risdiplam or to the constituents of its formulation
Treatment with oral salbutamol or another beta-2 adrenergic agonist taken orally for SMA is not allowed. Use of inhaled beta-2 adrenergic agonists is allowed
Infants exposed to drugs with known retinal toxicity given to mothers during pregnancy (and lactation) should not be enrolled. Anticipated need for drugs known to cause retinal toxicity during the study.
Diagnosis of ophthalmic diseases

sponsor: Hoffmann-La Roche

contacts: Reference Study ID Number: BN40703 Https://forpatients.roche.com/, 888-662-6728 (U.S. and Canada), [email protected]

investigators: Clinical Trials,Hoffmann-La Roche

trial center locations: United States,Australia,Belgium,Brazil,China,Italy,Poland,Russian Federation,Saudi Arabia,Taiwan

• A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
  
  
• A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
  
  
• A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
  
  
• A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
  
  
• A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
  
  
• A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
  
  
• A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
  
  
• A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
  
  
• A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
  
  
• A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
  
  
• A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
  
  
• A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
  
  
• A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
  
  
• A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
  
  
• A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy